Nanosyn Inc

Synthego, located in Redwood City, CA, specializes in providing advanced solutions for CRISPR-based therapeutics, facilitating the development of cell and gene therapies. With a focus on research-use only (RUO) products and regulatory expertise, Synthego supports the entire continuum from discovery to clinical trials, offering a range of CRISPR technologies including gRNA and nucleases. Committed to accelerating life science research and improving human health, Synthego emphasizes high fidelity and affordability in its offerings. Their dedication to regulatory compliance and innovative products, such as the GMP-grade SpCas9 nuclease and essential RNA enzymes, ensures they meet the needs of researchers navigating the complexities of therapeutic development. Generated from the website

Allakos Inc, based in San Carlos, CA, is a biopharmaceutical company dedicated to developing therapeutic antibodies that target immunomodulatory receptors on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Their lead programs focus on inhibiting mast cell and eosinophil activation, as these cells play a pathogenic role in various inflammatory conditions. With a focus on novel biology, Allakos is conducting Phase 2 studies in Chronic Spontaneous Urticaria and Atopic Dermatitis, utilizing investigational monoclonal antibodies such as Lirentelimab (AK002) to deplete eosinophils and inhibit mast cells, and AK006 to selectively and potently inhibit mast cells, including KIT mediated signaling. Their commitment lies in addressing the needs of patients suffering from chronic inflammatory diseases through innovative therapeutic approaches.Generated from the website

Elevian, Inc., based in Menlo Park, CA, is dedicated to developing innovative medicines that facilitate recovery and regeneration, particularly in the aftermath of stroke—a leading cause of long-term disability and death worldwide. Their lead program focuses on a recombinant protein known as rGDF11, which has shown promise in enhancing recovery after both ischemic and hemorrhagic strokes by promoting neovascularization, neurogenesis, and reducing inflammation. In addition to stroke, Elevian's rGDF11 has demonstrated potential benefits in treating various aging-related diseases, making it a versatile candidate for addressing multiple health challenges associated with aging. The company's commitment to kindness, diligence, openness, community, responsibility, and enjoyment underscores its mission to transform the future of medicine. Generated from the website